Pharma executive blames vague DEA rules for opioid epidemic

CHARLESTON, W.Va. (AP) — A drug company executive testifying in a landmark trial against three large opioid distributors has continued to blame the Drug Enforcement Administration for West Virginia's addiction epidemic, saying his company's internal controls went beyond what regulations require.

David May, the vice president of corporate security and diversion control for the AmerisourceBergen Drug Co., testified Monday that the company's abuse prevention systems have gone beyond the DEA's expectations and federal regulations, and have been improved over the years through more digital monitoring and training, according to The Herald-Dispatch.

The testimony came in a civil case brought by Cabell County and the city of Huntington that accuses AmerisourceBergen, Cardinal Health Inc. and McKesson Corp. of fueling the U.S. opioid epidemic. An expert witness for the county and Huntington city used data compiled by the federal government to show that pharmaceutical distributors shipped nearly 128 million doses of prescription opioids to the county from 2006 to 2014 — or more than 140 a year for every man, woman and child in the county.

The companies, in turn, say poor communication and pill quotas set by federal agents are to blame, along with a rise in prescriptions written by doctors.

The regulations identify a suspicious order as one of unusual quantity, one that deviates from the usual pattern or one that is frequent, May testified. There's no set quantity that determines whether an order would be flagged, and no additional guidance on determining suspicious activity, he said.

Last week, Cabell County attorney Paul T. Farrell Jr. pointed to an internal memo noting how many pills pharmacies could order without triggering an alert. The memo said a small pharmacy could order 350,000 hydrocodone or oxycodone pills a year,...